|
|
Learning Objective:
By the end of the presentation the participants will be able to:
1. Understand viral hepatitis and HIV risks for IDU.
2. Know the number and types of CDC HIV/AIDS interventions and programs for IDU.
3. Incorporate viral hepatitis risk reduction techniques into HIV prevention programs for IDU.
Background:
The proportion of HIV/AIDS diagnoses attributed to injection drug use has declined from approximately 33% in 1999 to about 29% in 20021. However, recent studies show high prevalence of hepatitis B and hepatitis C virus in this group. Further, studies of IDU behavior suggest that specific risk reduction techniques (e.g., washing hands, not sharing drug solution, staunching blood flow with absorbent pad after injection) that may reduce viral hepatitis and HIV transmission are not being practiced among IDU, and therefore need to be incorporated into existing HIV and viral hepatitis prevention programs for IDU. CDC funds 141 CBOs to conduct HIV/AIDS prevention activities. Approximately 32 programs (23%) will reach a large proportion of IDU. There are many opportunities to integrate viral hepatitis prevention messages.
1CDC, HIV/AIDS Surveillance Report 2002, 14
Setting:
Viral hepatitis and HIV/AIDS prevention and intervention programs.
Population e.g. API Youth, MSM, IDU:
Adult Injection drug users (IDU(, youth IDU
Project Description:
Gaps in prevention messages as indicated by behavioral studies in the current literature, and a description of CDC funded HIV/AIDS programs and evidence based interventions for IDU will be presented. Participants will learn how specific viral hepatitis messages and programs can be incorporated into prevention programs for IDU.
Results/Lessons Learned:
Prevention programs should incorporate viral hepatitis messages for IDU.
Web Page: www.cdc.gov/idu
See more of F4 - Hepatitis Integration into HIV Prevention Programs for Injection Drug Users
See more of The 2005 National Viral Hepatitis Prevention Conference